Disease · MONDO_0005770

genital herpes

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. genital herpes. Diseases, record MONDO_0005770. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005770

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: genital herpes; Open Targets
Open Targets ID: MONDO_0005770; Open Targets
Other names: Genital herpes simplex (disorder), Virus-Genital Herpes, herpes genitalia, herpes genitalis, venereal herpes; Open Targets
Disease Ontology: DOID:8704; Disease Ontology
MeSH: D006558; MeSH
NCI Thesaurus: C14364; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 9 drugs, from DailyMed and FDA; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FAMCICLOVIR	CHEMBL880	Small molecule	Approval	DailyMed	22	5	5	Drugs and targets
VALACYCLOVIR	CHEMBL1349	Small molecule	Approval	DailyMed	6	5	5	Drugs and targets
ACYCLOVIR	CHEMBL184	Small molecule	Approval	DailyMed and FDA	41	3	3	Drugs and targets
VALACYCLOVIR HYDROCHLORIDE	CHEMBL1201110	Small molecule	Approval	DailyMed	60	2	2	Drugs and targets
ACYCLOVIR SODIUM	CHEMBL1200380	Small molecule	Approval	DailyMed	5	2	2	Drugs and targets
AMENAMEVIR	CHEMBL4297592	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
POLYETHYLENE GLYCOL	CHEMBL1201478	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
QS-21	CHEMBL4297817		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 1/2	TTD	1	0	0	Drugs and targets

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/5426	Drugs and targets
POLE2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/5427	Drugs and targets
POLE3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/54107	Drugs and targets
PRIM1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1/2	https://conductscience.org/library/genes/5557	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00306787	Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes	Phase 3	1,179	2011-06-17	Genital Herpes	FAMCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00477334	Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients	Phase 4	463	2011-03-16	Genital Herpes	FAMCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00158860	A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.	Phase 4	384	2019-02-15	Herpes Genitalis	VALACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT01281007	Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes	Phase 3	150	2015-07-07	GENITAL HERPES	ACYCLOVIR, FAMCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT01687595	Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes	Phase 2	80	2021-07-13	Herpes Simplex Type 2	QS-21	Its record names the disease	ClinicalTrials.gov
NCT00495716	Effect of HSV-2 Suppressive Therapy on Sexual Behavior	Phase 4	72	2020-01-29	Genital Herpes	ACYCLOVIR SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00362297	Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2	Phase 4	31	2014-10-08	Genital Herpes	ACYCLOVIR SODIUM, VALACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT01453075	Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)	Phase 1	31	2016-11-22	Chronic Hepatitis C Infection	VALACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00171990	Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes	Phase 3	1,461		Recurrent Genital Herpes	FAMCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00486200	A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes	Phase 2	695		Herpes Genitalis	AMENAMEVIR, VALACYCLOVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Famciclovir vs Valacyclovir: serious adverse events	2 of 371	1 of 385	756	NCT00306787	Trial comparisons
Valaciclovir 1g QD vs Placebo: deaths from any cause	1 of 255	0 of 128	383	NCT00158860	Trial comparisons
Valaciclovir 1g QD vs Placebo: serious adverse events	3 of 255	4 of 128	383	NCT00158860	Trial comparisons
Famciclovir 1000 mg vs Placebo Comparator: serious adverse events	2 of 206	1 of 98	304	NCT00477334	Trial comparisons
Famciclovir 1000 mg vs Placebo Comparator: Number of Participants With a Second Recurrence of Genital Herpes in the Follow-up Period	141 of 185	75 of 92	277	NCT00477334	Trial comparisons
Famciclovir 125 mg vs Aciclovir 200 mg: serious adverse events	0 of 75	0 of 75	150	NCT01281007	Trial comparisons
HerpV + QS-21 vs Placebo: serious adverse events	3 of 70	0 of 10	80	NCT01687595	Trial comparisons
Episodic Treatment Arm vs Suppressive Therapy Arm: serious adverse events	0 of 35	0 of 37	72	NCT00495716	Trial comparisons
HerpV + QS-21 vs Placebo: Number of Participants With Peripheral Blood Mononuclear Cell Immune Response at Any Time	46 of 61	1 of 8	69	NCT01687595	Trial comparisons
HerpV + QS-21 vs Placebo: Number of Participants With CD8+ Immune Response at Any Time	32 of 61	2 of 8	69	NCT01687595	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
16044019	RESULT	1	PubMed
22225814	DERIVED	1	PubMed
20070143	DERIVED	1	PubMed
19192993	DERIVED	1	PubMed
18621575	DERIVED	1	PubMed
18596069	DERIVED	1	PubMed
18593294	DERIVED	1	PubMed
17314338	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005770

GET https://conductscience.org/api/diseases/v1/MONDO_0005770/drugs

API reference For AI assistants